Kosmos Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company developing an astrobiological therapeutic platform focused on the treatment of post-evolutionary disease in zero-gravity celestial settings, closed a whopping $319M Series A financing. Participants include Apple Ventures, Omniscient Venture Partners, Clairvoyant Capital, NASA Bioventures and Crystal Ball Ventures.

_________________________________________________________________________

Wishing you a happy April Fool’s
And no joke…OnBioVC 1Q10 Trend Analysis release next week